ライフサイエンスコーパス: postpartum women

1 for those at 37-42 weeks in comparison with postpartum women.

2 of calcium supplementation (1 g per day) in postpartum women.

3 requently used as the baseline in studies of postpartum women.

4 les as did 5 of 97 army recruits and 2 of 50 postpartum women.

5 necessary to assess if TENS could be used in postpartum women.

6 th anxiety disorders, including pregnant and postpartum women.

7 tion may influence Lactobacillus recovery in postpartum women.

8 disorder, and opioid-related overdose among postpartum women.

9 rs may lead to reduced IPV among pregnant or postpartum women.

10 he leading cause of death among pregnant and postpartum women.

11 continued use, and adherence in pregnant and postpartum women.

12 ed outpatient visits were among pregnant and postpartum women.

13 e used in 43 studies (0.4%) involving 22 095 postpartum women.

14 ission and loss to follow-up of pregnant and postpartum women.

15 mographic characteristics, and the OHRQoL in postpartum women.

16 e EPDS-9 versus full EPDS among pregnant and postpartum women.

17 tment and no treatment trials in pregnant or postpartum women.

18 (REE) and total energy expenditure (TEE) in postpartum women.

19 or viral decline in a cohort of HCV-infected postpartum women.

20 ession, including depression in pregnant and postpartum women.

21 ired ability to mount a boosting response in postpartum women.

22 ral adult population, including pregnant and postpartum women.

23 ive behavioral therapy (CBT) in pregnant and postpartum women.

24 ting ART use among HIV-infected pregnant and postpartum women.

25 ent and distressing symptoms in pregnant and postpartum women.

26 esearch gaps in tuberculosis in pregnant and postpartum women.

27 th anxiety disorders, including pregnant and postpartum women.

28 isk of psychiatric disorders in pregnant and postpartum women.

29 se events should be particularly targeted to postpartum women.

30 10 with major depression, 15 healthy) and 24 postpartum women (13 with major depression, 11 healthy).

31 significantly shorter than that observed in postpartum women (148 vs 256 h; P<.001), and the median

32 Among pregnant and postpartum women 18 years and older, 6 trials (n = 11,86

33 this quantity to be significantly reduced in postpartum women, 20.6+/-1.7 versus 26.1+/-2.0 mmHg in c

34 Among postpartum women, 89% were extubated, 89% recovered, and

35 pation increased by 7.22% among pregnant and postpartum women (95% CI, 2.54%-12.12%), 4.96% among inf

36 Further information on how mobile postpartum women access and remain in care would be inst

37 Postpartum women across all groups were less likely to b

38 Six hundred antenatal and postpartum women aged 18-39 y were randomized to an HIV

39 , 4, 6, 12, and 18 mo postparturition in 115 postpartum women aged 20-40 y (parity: 0-1).

40 y ratio more than tripled among pregnant and postpartum women aged 35 to 44 years from 4.9 (95% CI, 3

41 y ratio more than tripled among pregnant and postpartum women aged 35 to 44 years, consistent with in

42 In pregnant and postpartum women, AI-guided screening using a digital st

43 sulfadoxine or pyrimethamine in prepartum or postpartum women, although partum status did have a sign

44 Among low-income postpartum women, an internet-based weight loss program

45 in SARS-CoV-2 in convalescent plasma from 36 postpartum women and 14 of their infants infected with S

46 ing special populations such as pregnant and postpartum women and immunocompromised patients.

47 ses genital tract infections in pregnant and postpartum women and respiratory infections in neonates.

48 d the gut microbiota profile in pregnant and postpartum women and their infants.

49 of-care oral iron could alleviate anaemia in postpartum women and their infants.

50 rovides nutritional support for pregnant and postpartum women and young children.

51 Data were reported for 94 pregnant women, 8 postpartum women, and 137 nonpregnant women of reproduct

52 cases of invasive GBS disease in pregnant or postpartum women, and 57000 (UR, 12000-104000) fetal inf

53 ith anxiety disorders, including pregnant or postpartum women, and compared clinical outcomes and har

54 ase, especially among older adults, pregnant/postpartum women, and neonates.

55 Postpartum women are at increased risk of developing pue

56 onavirus Disease 2019 (COVID-19) pandemic on postpartum women are of increasing concern among mental

57 depression among Latina and African American postpartum women are similar to epidemiologic rates for

58 or-blind, clinical trial enrolling 371 adult postpartum women at 12 clinics in WIC programs from the

59 d bone turnover markers were measured in 115 postpartum women at 2 weeks, 2 months, 4 months, 6 month

60 alth-care workers providing clinical care to postpartum women at 39 hospitals implementing the E-MOTI

61 We suggest that pregnant and postpartum women at a high risk of PrAKI should be ident

62 inty that providing or referring pregnant or postpartum women at increased risk to counseling interve

63 s and acellular pertussis (Tdap) vaccine for postpartum women before hospital discharge.

64 disorder in many Latina and African American postpartum women begins before delivery, revealing the n

65 dy levels, and whether this was different in postpartum women compared with control women.

66 tric mean titer (GMT) ratio for HPV-16 among postpartum women compared with historical controls.

67 risk of stroke by age group in pregnant and postpartum women compared with their nonpregnant contemp

68 Two to four weeks postpartum, women completed a 91-item survey by telephon

69 s, and Children (WIC program) for low-income postpartum women could produce greater weight loss than

70 hat in the second trimester of pregnancy and postpartum women did not show differences in their PPS s

71 health care has increased, many pregnant and postpartum women do not receive the recommended number o

72 97%; specificity, 50% to 89%), pregnant and postpartum women (Edinburgh Postnatal Depression Scale:

73 ss episodes among 8,323 healthy pregnant and postpartum women enrolled in a Puget Sound region, Washi

74 At 9 months postpartum, women enrolled in Healthy Options demonstrat

75 Ten to twenty percent of postpartum women experience anxiety or depressive disord

76 Pregnant and postpartum women experienced higher rates of influenza-a

77 , including invasive disease in pregnant and postpartum women, fetal infection/stillbirth, and infant

78 (3) how to screen and diagnose pregnant and postpartum women for active and latent tuberculosis; (4)

79 idence suggested that screening pregnant and postpartum women for depression may reduce depressive sy

80 ding multiple HIV self-tests to pregnant and postpartum women for secondary distribution is more effe

81 r review of 17 cases of botulism in pregnant/postpartum women found that more than half required vent

82 Although postpartum women frequently experience pain that interfe

83 in blood and residential tap water from 150 postpartum women from three U.S. locations.

84 Pituitaries from pregnant and postpartum women had a fivefold higher apoptotic index c

85 Postpartum women had reduced Plasmodium spp. antibody le

86 Past-year pregnant and postpartum women had significantly lower rates of alcoho

87 l study representing more than 10 million US postpartum women, HDP was associated with higher odds of

88 r among pregnant (HR 1.3, 95% CI 0.5-2.1) or postpartum women (HR 1.1, 95% CI 0.6-1.6) than among non

89 gle-large-dose vitamin A supplementation for postpartum women in areas of prevalent vitamin A deficie

90 s-sectional, multicenter study involved 1745 postpartum women in Brazil.

91 by the total count of deaths of pregnant and postpartum women in each state.

92 95% CI 0.6-1.6) than among non-pregnant/non-postpartum women in five studies with available data.

93 s such as targeted screening of pregnant and postpartum women in high-risk groups should be evaluated

94 pective study of incident HIV among pregnant/postpartum women in Kenya were randomly divided into der

95 ial Organ Failure Assessment in pregnant and postpartum women in predicting severe maternal outcome.

96 donated milk, other supplementation) used by postpartum women in Seattle, WA (USA).

97 sting and couples testing among pregnant and postpartum women in sub-Saharan Africa is essential for

98 categorical 2012 PRAMS survey responses from postpartum women in the US to calculate original prevale

99 To advance inclusion of pregnant and postpartum women in tuberculosis drug trials, the US Nat

100 Over 12 weeks, mean antibody levels in postpartum women increased to levels observed in control

101 ied analyses for key subgroups (pregnant and postpartum women, infants younger than 1 year, and child

102 ng the population (HIV-infected pregnant and postpartum women), intervention (ART), and outcomes of i

103 in a more diverse population of pregnant and postpartum women, like women with high risk pregnancies

104 icy specifically directed towards supporting postpartum women living in low SES by ameliorating some

105 tly TNF-alpha monofunctional in pregnant and postpartum women living with and without HIV, with fever

106 Pregnant and postpartum women living with HIV (WLWH) need support for

107 implemented 3 interventions for pregnant and postpartum women living with HIV in 2019: (1) high-risk

108 is on service strengthening for pregnant and postpartum women living with HIV to reduce perinatal HIV

109 nitiation appears frequently in pregnant and postpartum women living with human immunodeficiency viru

110 different between lactating and nonlactating postpartum women matched for age, body weight, and adipo

111 Postpartum women may be microchimeric to offspring hemat

112 Among 460 371 postpartum women (mean [SD] age at delivery, 29.0 [10.8]

113 invasive ventilation, in contrast to 95% of postpartum women (median gestational age at delivery 30

114 invasive ventilation, in contrast to 95% of postpartum women (median gestational age at delivery 30

115 A total of 120 postpartum women meeting DSM-IV criteria for major depre

116 For pregnant and postpartum women, micronutrient supplementation should b

117 nter sample of pregnant women (N = 2876) and postpartum women (N = 1536).

118 antly between unipolar depressed and healthy postpartum women or between bipolar and healthy subjects

119 ions for perinatal depression in pregnant or postpartum women or their children.

120 ser but was consistent with the evidence for postpartum women regarding the benefits of screening, th

121 use severe illness and death in pregnant and postpartum women; regardless of the results of rapid ant

122 sed pregnant women but elevated in depressed postpartum women relative to matched healthy comparison

123 2013 to 2018, including 24% of pregnant and postpartum women reporting unmet health care need and 60

124 12 (80% [95% CI, 51.9%-95.7%]) pregnant and postpartum women, respectively (P > .99).

125 1 (73.3% [95% CI, 44.9%-92.2%]) pregnant and postpartum women, respectively (P = .03).

126 ent decreased in 96% and 89% of pregnant and postpartum women, respectively.

127 ent decreased in 96% and 89% of pregnant and postpartum women, respectively.

128 Five HIV(-) and 6 HIV(+) postpartum women returned 2-3 months after delivery for

129 RSA is an increasingly important pathogen in postpartum women; risk factors for postpartum SA breast

130 e in addressing shortcomings in pregnant and postpartum women's health care, amidst systems that do n

131 he annual incidence was 5 times higher among postpartum women than pregnant women (511.2 vs. 95.8 per

132 In this cohort study of postpartum women, the incidence of initiation of postnat

133 ons, including older adults and pregnant and postpartum women; the accuracy of depression screening i

134 died--nonpregnant women, pregnant women, and postpartum women (those who had delivered < or = 2 weeks

135 nitive approaches incentivizing pregnant and postpartum women to seek substance use disorder treatmen

136 matic clinical trial randomized pregnant and postpartum women to usual care or artificial intelligenc

137 In all, 18 pregnant women and 4 postpartum women (total, 22 of 102 [22%]) required inten

138 ulative incidence of PAS per 100000 pregnant/postpartum women vs nonpregnancy-associated stroke (NPAS

139 o 24 years was 14 events per 100000 pregnant/postpartum women vs NPAS incidence of 6.4 per 100000 non

140 for venous thromboembolism among pregnant or postpartum women was 4.29 (95% CI, 3.49 to 5.22;P < 0.00

141 GFR in postpartum women was elevated above control values by 41

142 ccination regimen given 6 months apart among postpartum women was noninferior to a 3-dose regimen amo

143 ibutable risks in comparable nonpregnant and postpartum women were 1.91 (95% CI 1.51-2.31) and 1.16 (

144 nts with postpartum psychosis and 64 healthy postpartum women were included.

145 At 2 wk postpartum, women were randomly assigned to consume 1 ca

146 At 2 wk postpartum, women were randomly assigned to receive eith

147 clinically relevant weight loss in lactating postpartum women, which was sustained at 9 mo after trea

148 sectional study of 460 371 privately insured postpartum women who delivered a singleton live newborn

149 ycemic clamp with stable isotopes, in 6-week postpartum women who were lactating (n = 12) or formula-

150 iral therapy and HIV-uninfected pregnant and postpartum women who were naive to Covid-19 vaccination.

151 gesterone replacement reduces cocaine use in postpartum women with a cocaine use disorder (CUD).

152 ort the promise of progesterone treatment in postpartum women with a CUD and could constitute a thera

153 Pregnant but not postpartum women with a personal or family history of de

154 the risks of disturbed sleep to pregnant and postpartum women with bipolar disorder, as well as struc

155 (DBSs) to predict future viral load (VL) in postpartum women with HIV on antiretroviral therapy (ART

156 r, these levels were significantly higher in postpartum women with major depression across time inter

157 plasma melatonin differentiate pregnant and postpartum women with major depression from matched preg

158 This association was not found among postpartum women with major depression or postpartum hea

159 ally relevant and sustainable weight loss in postpartum women with overweight and obesity.

160 a racially and ethnically diverse cohort of postpartum women with recent GDM.

161 ults for the benefit of CBT for pregnant and postpartum women with screen-detected depression showed

162 Among 86 pregnant and postpartum women with severe COVID-19 who received compa

163 Among 86 pregnant and postpartum women with severe COVID-19 who received compa

164 At 3 months postpartum, women with asthma retained 10.4 kg (95% CI:

165 Participants were 1,654 postpartum women within a year of giving birth.

166 fication treatment to produce weight loss in postpartum women within the primary health care setting

167 Controls were randomly selected postpartum women without VTE, matched on birth year.

168 Findings estimate that 20-43 pregnant/postpartum women would need to be vaccinated with an 80%

169 ing outcomes among HIV-infected pregnant and postpartum women, yet rates of initiation, adherence, an